Search Within

Alan Loh Ho

Formats
  1. Journal Article (111)
  2. Meeting Abstract (104)
  3. Review (7)
  4. Editorial (4)
  5. Guidelines (4)
  6. Research Letter (4)
  7. Book Section (2)
  8. Miscellaneous (1)
Groups
  1. Department of Medicine (237)
  2. Head and Neck Service (237)
  3. Solid Tumor Oncology Division (237)
  4. Department of Pathology and Laboratory Medicine (93)
  5. Surgery (78)
  6. GSK Faculty (69)

More Groups

People
  1. David Pfister (89)
  2. Eric Sherman (84)
  3. Lara Dunn (53)
  4. Nora Katabi (48)
  5. Nancy Lee (42)
  6. Sofia Haque (40)

More People

Years
  1. 2025 (5)
  2. 2024 (25)
  3. 2023 (26)
  4. 2022 (23)
  5. 2021 (18)
  6. 2020 (21)

More Years

Publications
  1. Journal of Clinical Oncology (73)
  2. Annals of Oncology (20)
  3. International Journal of Radiation Oncology, Biology, Physics (14)
  4. Cancer Research (10)
  5. Clinical Cancer Research (8)
  6. Journal of the National Comprehensive Cancer Network (8)

More Publications

Publishers
  1. American Society of Clinical Oncology (75)
  2. Elsevier Inc. (27)
  3. Oxford University Press (24)
  4. American Association for Cancer Research (23)
  5. Springer (11)
  6. Wiley Blackwell (11)

More Publishers

Results (237)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • NCCN Guidelines® Insights: Squamous cell skin cancer, version 1.2022 Featured Updates to the NCCN Guidelines
    Guidelines

    Schmults, C. D.; Blitzblau, R.; Aasi, S. Z.; Alam, M.; Andersen, J. S.; Baumann, B. C.; Bordeaux, J.; Chen, P. L.; Chin, R.; Contreras, C. M.; more...
    Journal of the National Comprehensive Cancer Network (2021)

    Fulltext@MSK | Save
  • Androgen receptor pathway in salivary gland cancer
    Editorial

    Ho, A. L.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • First report of the safety/tolerability and preliminary antitumor activity of HB-201 and HB-202, an arenavirus-based cancer immunotherapy, in patients with HPV16+ cancers
    Meeting Abstract

    Ho, A. L.; Posner, M. R.; Niu, J.; Fu, S.; Leidner, R. S.; Pearson, A. T.; Chung, K. Y.; Richardson, D. L.; Wang, D.; Pimentel, A.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • The AIM-HN Study: A pivotal study evaluating the efficacy of tipifarnib in patients with recurrent or metastatic head and neck squamous cell carcinoma with HRAS mutations
    Meeting Abstract

    Haddad, R. I.; Adkins, D.; Licitra, L. F.; Bruce, J. Y.; Gillison, M. L.; Ahn, M. J.; Hsieh, C. Y.; Wang, H. M.; Psyrri, A.; Machiels, J. P. H.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Randomized phase II study of sorafenib with or without everolimus in patients with radioactive iodine refractory Hurthle cell thyroid cancer (HCC) (Alliance A091302/ ITOG 1706)
    Meeting Abstract

    Sherman, E. J.; Foster, N. R.; Su, Y. B.; Shergill, A.; Ho, A. L.; Konda, B.; Ghossein, R. A.; Ganly, I.; Schwartz, G. K.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • A phase II trial cohort of nivolumab plus ipilimumab in patients (Pts) with recurrent/metastatic salivary gland cancers (R/M SGCs)
    Meeting Abstract

    Burman, B.; Sherman, E. J.; Dunn, L.; Fetten, J. V.; Michel, L. S.; Morris, L. G. T.; Ostrovnaya, I.; Haque, S.; Pfister, D. G.; Ho, A. L.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • The gamma secretase inhibitor AL101 combined with other drugs for dual targeting of Notch dysregulated tumors
    Meeting Abstract

    Ferrarotto, R.; Rauch, R.; Leibovich, T.; Shitrit, A.; Solomon, O.; Herz, E.; Walker, R. M.; Ho, A. L.; Kaye, J.
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Safety, efficacy, immunogenicity of arenavirus-based vectors HB-201 and HB-202 in patients with HPV16+ cancers
    Meeting Abstract

    Posner, M. R.; Ho, A. L.; Niu, J.; Nabell, L.; Leidner, R. S.; Nieva, J.; Richardson, D. L.; Pearson, A. T.; Wang, D.; Chung, K.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • ACCURACY: A phase II trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut): Results of 6-mg cohort
    Meeting Abstract

    Ho, A. L.; Bowles, D. W.; Even, C.; Hao, D.; Kang, H.; Metcalf, R.; Muzaffar, J.; Oliva, M.; Perez, C. A.; Popovtzer, A.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • An open-label, phase II, multicenter, single-arm study of induction and concurrent vismodegib combined with curative-intent radiation therapy for locally advanced basal cell carcinoma
    Meeting Abstract

    Yom, S.; Arron, S.; Ho, A.; Algazi, A.; Dunn, L.; Tsai, C. J.; Humphries, A.; Hultman, C.; Grekin, R.; Knott, P. D.; more...
    American Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save